Erwiderung

Die Aussagen der S2k-Leitlinie „Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter“ [1] entsprechen dem wissenschaftlichen Stand zum Zeitpunkt der Erstellung.

^* für die Leitlinienkommission der S2k-LL „Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter“ der Deutschen Diabetes Gesellschaft.

• Literatur

• 1 Bahrmann A, Bahrmann P, Baumann J. et al. S2k-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter. Diabetologie 2018; 13: 423-489
• 2 Van de Laar FA, Lucassen PL, Akkermans RP. et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005 (2):CD003639. DOI: 10.1002/14651858.CD003639.pub2
• 3 Van de Laar FA, Lucassen PL. α-Glucosidase- Inhibitors for Patients With Type 2 Diabetes. Diabetes Care 2005; 28: 1841
• 4 Van de Laar FA, Lucassen PL. No evidence for a reduction of myocardial infarctions by acarbose. European Heart Journal 2004; 25: 1179-1180
• 5 Chen JM, Chang CW, Lin YC. et al. Acarbose Treatment and the Risk of Cardiovascular Disease in Type 2 Diabetic Patients: A Nationwide Seven-Year Follow-Up Study. Cardiovasc Drugs Ther 2017; 31: 401-411
• 6 Holman RR, Coleman RL, Chan JCN. et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): A randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5: 877-886
• 7 Asakura M, Kim J, Asanuma H. et al. Does treatment of impaired glucose tolerance improve cardiovascular outcomes in patients with previous myocardial infarction?. Cardiovasc Drugs Ther 2017; 31: 401-411
• 8 Tseng YH, Huang HL, Chu FY. et al. Use of an α-Glucosidase Inhibitor and the Risk of Colorectal Cancer in Patients With Diabetes: A Nationwide, Population-Based Cohort Study. Diabetes Care 2015; 38: 2068-2074